TY - JOUR AU - Zhu, You-Cai AU - Wan, Bing AU - Wu, Li-Xin AU - Li, Xing-Liang AU - Wang, Wen-Xian AU - Xu, Chun-Wei AU - Zhuang, Wu AU - Wei, Jian-Guo AU - Du, Kai-Qi PY - 2019 TI - Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib JF - Translational Cancer Research; Vol 8, No 4 (August 31, 2019): Translational Cancer Research Y2 - 2019 KW - N2 - Chromosomal translocation resulting in the fusion between the echinoderm microtubule-associated protein-like 4 ( EML4 ) gene and the anaplastic lymphoma kinase ( ALK ) gene has been considered as a novel oncogenic fusion in a subset of non-small cell lung cancer ( NSCLC ), mostly in non-smokers with adenocarcinoma. EML4-ALK translocations are commonly reported to be mutually exclusive with epidermal growth factor receptor (EGFR) or KRAS mutations. Herein, we reported a rare case of 47-year-old female was diagnosed with lung adenocarcinoma and treated with three cycles of chemotherapy. A biopsy acquired after disease progression revealed concurrent KRAS mutation and ALK translocation by an next-generation sequencing (NGS) assay. The patient had a favorable tumor response to crizotinib, a tyrosine kinase inhibitor (TKI). A further understanding of the molecular biology with multiple oncogenic drivers will promote the optimal treatment for NSCLC. UR - https://tcr.amegroups.org/article/view/29743